The coronavirus pandemic (COVID-19) is spreading worldwide, with more than 27. 47 million reported cases. With the spread of the virus, scientists rush to download approval for candidate vaccines opposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a causal agent of COVID-19 disease and multisistmic inflammatory syndrome in young people (MIS-C).
Some prospective vaccines are undergoing clinical evaluation lately. One of the most promising candidate vaccines is AZD1222 or ChAdOx1 nCoV-19, which evolved through scientists from the University of Oxford and AstraZeneca, an Anglo-Swedish multinational pharmaceutical and biopharmaceutical company.
AZD1222 is one of the vaccines in the Phase 3 clinical trial. Phase 3 trials compare a new drug to the popular drug. These trials evaluate the side effects of the drug and which drug works best. Phase 3 trials recruit a hundred or more patients. Despite promising initial results, the pharmaceutical company discontinued phase 3 trials of the SARS-CoV-2 vaccine in progression due to a potentially unexplained disease in one of the trial participants.
Among the more than 179 vaccines requesting COVID-19, ChAdOx1 nCoV-19 is one of 34 vaccines being tested in humans, of which nine have entered the penultimate phase of human trials, which will determine whether the vaccine will be approved for public use. .
In July, the initial effects of protection and efficacy revealed that more than two-thirds of participants who won the possible vaccine reported headaches and fatigue after being vaccinated. In some of the participants, fever and muscle pain were experienced, but no serious adverse effects. It was reported.
The vaccine, which is a recombinant viral vector vaccine, uses an adenovirus that carries a gene for one of the proteins in SARS-CoV-2, the virus that causes COVID-19. Adenovirus, which is a weakened edition of a chimpanzee bloodless virus, will be used to induce an immune reaction to protect the body from infection. AstraZeneca authorized the vaccine in April from Oxford University.
The phase 3 trial aimed to recruit approximately 30,000 participants at sites in the United States.
The company announced that the trial had been suspended due to a suspected serious adverse reaction at a volunteer in the UK.
A spokesman for AstraZeneca told Stat News in a statement that the company’s popular review procedure had led to a pause in vaccination, allowing the company to review safety data. However, the nature of the reaction and when it happened are not yet clear, however, the patient deserves a full recovery.
“In ongoing global randomized controlled trials of the Oxford coronavirus vaccine, our popular review procedure caused a pause in vaccination to allow review of protection data. This is a regimen action that occurs whenever there is a potentially unexplained disease in any of the trials, while under investigation, ensuring that we maintain the ‘integrity of the test’, AstraZeneca said in a statement.
“In giant trials, diseases will happen by chance, but they will have to be independently tested to determine this carefully. We are working to speed up the review of the bachelor occasion to minimize any possible effect on the trial schedule. We are committed to ensuring the protection of our participants and the highest criteria of conduct in our trials,” the firm added.
The duration of the Phase 3 pause is unclear; however, the progress of the vaccine, like the last 8 in Phase 3 trials, is being largely monitored worldwide as the pandemic spreads widely and affects 188 countries and territories.
The break can only plan trials in various states in the United Kingdom, Brazil, South Africa, the United States and India, which are believed to be the most affected countries.
Written by
Angela is a career and heart nurse, graduated by far (Cum Laude) from her Bachelor of Nursing degree from Baguio University, Philippines, is recently completing her master’s degree where she specialized in maternal and child nursing and has worked as a clinical instructor and educator at Baguio University School of Nursing.
Use one of the following to cite this article in your essay, job, or report:
Apa
Laguipo, Angela. (2020, September 08). AstraZeneca COVID-19 vaccine trial suspended due to suspected adverse reaction. News-Medical. Retrieved September 23, 2020 at https://www. news-medical. net/news/20200908/AstraZeneca-COVID-19-vaccine- trial-paused-due-to-suspicion-adverse-reaction. aspx.
Mla
Laguipo, Angela. ” Vaccine trial AstraZeneca COVID-19 suspended for suspected reaction”. News-Medical. 23 September 2020.
Chicago
Laguipo, Angela. “The AstraZeneca COVID-19 vaccine trial was suspended due to a suspected reaction. ” News-Medical. https: //www. news-medical. net/news/20200908/AstraZeneca-COVID-19-vaccine-trial-paused- due to suspicion: reaction. aspx. (cited 2020 Sep 23).
Harvard
Laguipo, Angela. 2020 The AstraZeneca COVID-19 vaccine trial has been discontinued due to suspected adverse reaction. News-Medical, 07 September 2020, https://www. news-medical. net/news/20200908/AstraZeneca-COVID -19-trial-of-vaccine-paused-due-to-suspect-adverse reaction. aspx.
News-Medical. net – An AZoNetwork site
Ownership and operation through AZoNetwork, © 2000-2020